{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:53:48Z","timestamp":1790736828381,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:00:00Z","timestamp":1688342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jules Coenegracht Sr Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Ductal carcinoma in situ (DCIS) is present in more than half of HER2-positive invasive breast cancer (IBC). Recent studies show that DCIS accompanying HER2-positive IBC can be completely eradicated by neoadjuvant systemic therapy (NST). Our aim was to determine the percentage of pathologic complete response of the DCIS component in a nationwide cohort and to assess associated clinicopathologic variables. Furthermore, the impact on surgical treatment after NST was investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Women diagnosed with HER2-positive IBC, treated with NST and surgery, between 2010 and 2020, were selected from the Netherlands Cancer Registry. Pre-NST biopsy and postoperative pathology reports were obtained from the Dutch Nationwide Pathology Databank and assessed for the presence of DCIS. Clinicopathologic factors associated with DCIS response were assessed using logistic regression analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A DCIS component was present in the pre-NST biopsy in 1403 (25.1%) of 5598 included patients. Pathologic complete response of the DCIS component was achieved in 730 patients (52.0%). Complete response of DCIS occurred more frequently in case of complete response of IBC (63.4% versus 33.8%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). ER-negative IBC (OR 1.79; 95%CI 1.33\u20132.42) and more recent years of diagnosis (2014\u20132016 OR 1.60; 95%CI 1.17\u20132.19, 2017\u20132019 OR 1.76; 95%CI 1.34\u20132.34) were associated with DCIS response. Mastectomy rates were higher in IBC+DCIS compared to IBC (53.6% versus 41.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pathologic complete response of DCIS occurred in 52.0% of HER2-positive IBC patients and was associated with ER-negative IBC and more recent years of diagnosis. Future studies should investigate imaging evaluation of DCIS response to improve surgical decision making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10549-023-07012-z","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T04:01:38Z","timestamp":1688356898000},"page":"227-235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis"],"prefix":"10.1007","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1024-3519","authenticated-orcid":false,"given":"Roxanne A. W.","family":"Ploumen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Claassens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes F. S.","family":"Kooreman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristien B. M. I.","family":"Keymeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje A. C. E.","family":"van Kats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Gommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Siesling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiemo J. A.","family":"van Nijnatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,3]]},"reference":[{"key":"7012_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/jncimonographs\/lgv023","volume":"2015","author":"V Amoroso","year":"2015","unstructured":"Amoroso V, Generali D, Buchholz T et al (2015) International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fifth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2013). J Natl Cancer Inst Monogr 2015:90\u201396. https:\/\/doi.org\/10.1093\/jncimonographs\/lgv023","journal-title":"J Natl Cancer Inst Monogr"},{"key":"7012_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/bjc.1957.43","volume":"11","author":"HJ Bloom","year":"1957","unstructured":"Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359\u2013377. https:\/\/doi.org\/10.1038\/bjc.1957.43","journal-title":"Br J Cancer"},{"key":"7012_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1155\/2007\/971816","volume":"29","author":"M Casparie","year":"2007","unstructured":"Casparie M, Tiebosch AT, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19\u201324. https:\/\/doi.org\/10.1155\/2007\/971816","journal-title":"Cell Oncol"},{"key":"7012_CR4","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10549-016-3862-4","volume":"158","author":"SC Doebar","year":"2016","unstructured":"Doebar SC, van den Broek EC, Koppert LB et al (2016) Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Res Treat 158:179\u2013187. https:\/\/doi.org\/10.1007\/s10549-016-3862-4","journal-title":"Breast Cancer Res Treat"},{"key":"7012_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403\u2013410. https:\/\/doi.org\/10.1111\/j.1365-2559.1991.tb00229.x","journal-title":"Histopathology"},{"key":"7012_CR6","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672\u20132685. https:\/\/doi.org\/10.1200\/JCO.1998.16.8.2672","journal-title":"J Clin Oncol"},{"key":"7012_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10549-021-06235-2","volume":"189","author":"EJ Groen","year":"2021","unstructured":"Groen EJ, van der Noordaa MEM, Schaapveld M et al (2021) Pathologic response of ductal carcinoma in situ to neoadjuvant systemic treatment in HER2-positive breast cancer. Breast Cancer Res Treat 189:213\u2013224. https:\/\/doi.org\/10.1007\/s10549-021-06235-2","journal-title":"Breast Cancer Res Treat"},{"key":"7012_CR8","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1016\/j.ejca.2012.05.023","volume":"48","author":"N Houssami","year":"2012","unstructured":"Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E (2012) Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 48:3342\u20133354. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.023","journal-title":"Eur J Cancer"},{"key":"7012_CR9","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1245\/s10434-011-2108-2","volume":"19","author":"M Kaufmann","year":"2012","unstructured":"Kaufmann M, von Minckwitz G, Mamounas EP et al (2012) Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 19:1508\u20131516. https:\/\/doi.org\/10.1245\/s10434-011-2108-2","journal-title":"Ann Surg Oncol"},{"key":"7012_CR10","doi-asserted-by":"publisher","first-page":"9934","DOI":"10.1038\/s41598-019-46309-2","volume":"9","author":"AJ Kole","year":"2019","unstructured":"Kole AJ, Park HS, Johnson SB, Kelly JR, Moran MS, Patel AA (2019) Overall survival is improved when DCIS accompanies invasive breast cancer. Sci Rep 9:9934. https:\/\/doi.org\/10.1038\/s41598-019-46309-2","journal-title":"Sci Rep"},{"key":"7012_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020235","author":"J Labrosse","year":"2021","unstructured":"Labrosse J, Morel C, Lam T et al (2021) The presence of an in situ component on pre-treatment biopsy is not associated with response to neoadjuvant chemotherapy for breast cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13020235","journal-title":"Cancers (Basel)"},{"key":"7012_CR12","unstructured":"NABON (2008) Dutch Guideline \u2018Treatment of breast cancer\u2019 (Richtlijn \u2018Behandeling van het Mammacarcinoom\u2019). Available at: https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/algemeen.html"},{"key":"7012_CR13","unstructured":"NABON (2012) Dutch Guideline \u2018Treatment of breast cancer\u2019 (Richtlijn \u2018Behandeling van het Mammacarcinoom\u2019). Available at: https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/algemeen.html"},{"key":"7012_CR14","unstructured":"NABON (2017) Dutch Guideline \u2018Treatment of breast cancer\u2019 (Richtlijn \u2018Behandeling van het Mammacarcinoom\u2019). Available at: https:\/\/richtlijnendatabase.nl\/richtlijn\/borstkanker\/algemeen.html"},{"key":"7012_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/bf00666201","volume":"32","author":"P O'Connell","year":"1994","unstructured":"O\u2019Connell P, Pekkel V, Fuqua S, Osborne CK, Allred DC (1994) Molecular genetic studies of early breast cancer evolution. Breast Cancer Res Treat 32:5\u201312. https:\/\/doi.org\/10.1007\/bf00666201","journal-title":"Breast Cancer Res Treat"},{"key":"7012_CR16","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/j.1365-2559.2006.02403.x","volume":"48","author":"K Park","year":"2006","unstructured":"Park K, Han S, Kim HJ, Kim J, Shin E (2006) HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48:702\u2013707. https:\/\/doi.org\/10.1111\/j.1365-2559.2006.02403.x","journal-title":"Histopathology"},{"key":"7012_CR17","first-page":"127","volume":"37","author":"S Steinman","year":"2007","unstructured":"Steinman S, Wang J, Bourne P, Yang Q, Tang P (2007) Expression of cytokeratin markers, ER-alpha, PR, HER-2\/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 37:127\u2013134","journal-title":"Ann Clin Lab Sci"},{"key":"7012_CR18","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1245\/s10434-019-07533-2","volume":"26","author":"S Sun","year":"2019","unstructured":"Sun S, van la Parra RFD, Rauch GM et al (2019) Patient selection for clinical trials eliminating surgery for HER2-positive breast cancer treated with neoadjuvant systemic therapy. Ann Surg Oncol 26:3071\u20133079. https:\/\/doi.org\/10.1245\/s10434-019-07533-2","journal-title":"Ann Surg Oncol"},{"key":"7012_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:134\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa1406281","journal-title":"N Engl J Med"},{"key":"7012_CR20","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1200\/jco.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch M, Rezai M, Loibl S et al (2010) Neoadjuvant treatment With trastuzumab in HER2-positive breast cancer: results from the geparquattro study. J Clin Oncol 28:2024\u20132031. https:\/\/doi.org\/10.1200\/jco.2009.23.8451","journal-title":"J Clin Oncol"},{"key":"7012_CR21","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-018-05082-y","volume":"174","author":"C van Dooijeweert","year":"2019","unstructured":"van Dooijeweert C, van Diest PJ, Willems SM, Kuijpers C, Overbeek LIH, Deckers IAG (2019) Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands. Breast Cancer Res Treat 174:479\u2013488. https:\/\/doi.org\/10.1007\/s10549-018-05082-y","journal-title":"Breast Cancer Res Treat"},{"key":"7012_CR22","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10549-011-1621-0","volume":"132","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Darb-Esfahani S, Loibl S et al (2012) Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy\/trastuzumab treatment in early breast cancer\u2013results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 132:863\u2013870. https:\/\/doi.org\/10.1007\/s10549-011-1621-0","journal-title":"Breast Cancer Res Treat"},{"key":"7012_CR23","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/jco.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH et al (2018) Human Epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update. J Clin Oncol 36:2105\u20132122. https:\/\/doi.org\/10.1200\/jco.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"7012_CR24","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1038\/sj.bjc.6605655","volume":"102","author":"H Wong","year":"2010","unstructured":"Wong H, Lau S, Yau T, Cheung P, Epstein RJ (2010) Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer 102:1391\u20131396. https:\/\/doi.org\/10.1038\/sj.bjc.6605655","journal-title":"Br J Cancer"},{"key":"7012_CR25","first-page":"1027","volume":"9","author":"W Wu","year":"2002","unstructured":"Wu W, Kamma H, Ueno E et al (2002) The intraductal component of breast cancer is poorly responsive to neo-adjuvant chemotherapy. Oncol Rep 9:1027\u20131031","journal-title":"Oncol Rep"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-023-07012-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-023-07012-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T16:29:43Z","timestamp":1689956983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-023-07012-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["7012"],"URL":"https:\/\/doi.org\/10.1007\/s10549-023-07012-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2731537\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,3]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships: Prof. Dr. Smidt reports grants from Nutricia and Servier Pharmaceuticals for microbiome research in colorectal cancer, not related to this study. Dr. T. van Nijnatten received institutional grant support from Bayer, and speaker honoraria from GE Healthcare and Bayer, not related to this study. L. Kooreman reports consulting fees from Novartis and educational fees from SCEM, not related to this study. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The current study was approved by the institutional ethics and privacy committee of The Netherlands Comprehensive Cancer Organization (IKNL) after reviewing the study protocol.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}